
The Liver Week 2020

Navigating Towards Precision Medicine with Current Knowledge in Liver Disease

August 13-14, 2020

VIRTUAL CONFERENCE

OUR PARTNERS

*The Liver Week 2020 is proud to introduce our partners.
We value your patronage and appreciate your confidence in us.*

Diamond	 YUHAN  BMS Pharmaceutical Korea Limited	 abbvie  Eisai	 Bayer  GILEAD
Platinum	 ILDONG  DONG-A ST		
Gold	 DAEWOONG PHARMACEUTICAL CO., LTD.  GC 녹십자	 IPSEN Innovation for patient care  BUKWANG PHARM. CO., LTD.	 Chong Kun Dang Pharm  <i>Samil</i>  SK plasma
Hybrid	 gsk  CELLTRION  astellas Leading Light for Life		
Blue	 SAMJIN  Hanmi  Pharma King  FERRING PHARMACEUTICALS		

The Liver Week 2020 Virtual Conference

08:40-09:00	The Liver Week 2020 Opening Ceremony	
09:00-09:05	ISALPDC Opening Ceremony	
09:00-10:10	KASL Symposium 1. Up-to-Date Treatment for Liver Diseases	Real Time Discussion <i>Dong Joon Kim (Hallym Univ.), Joo Hyun Sohn (Hanyang Univ.)</i>
09:00-09:20	Pharmacological Treatment of Alcoholic Hepatitis	<i>Gyongyi Szabo (Harvard Univ., USA)</i>
09:20-09:40	Pharmacological Treatment of Nonalcoholic Steatohepatitis	<i>Manal Abdelmalek (Duke Univ., USA)</i>
09:40-10:00	New Horizon of Immuno-Oncologic Therapy	<i>Amit Singal (UT Southwestern Medical Center, USA)</i>
10:00-10:10	Discussion	
09:00-10:10	PG1. Current Issues in Chronic Hepatitis B ^(*)	
09:00-09:10	Case Presentation and Key Questions	<i>Hyun Woong Lee (Yonsei Univ.)</i>
09:10-09:30	Immune Tolerant Chronic Hepatitis B: To Treat or Not?	<i>Jonggi Choi (Univ. of Ulsan)</i>
09:30-09:50	Risks and Benefits of Antiviral Therapy During Pregnancy	<i>Young-Sun Lee (Korea Univ.)</i>
09:50-10:10	Prophylactic Antiviral Therapy for Hepatitis B During Immunosuppressive Therapy	<i>In Hee Kim (Chonbuk National Univ.)</i>
09:05-11:00	ISALPDC 1. Obesity-Alcohol Synergism	Real Time Discussion <i>Won-IL Jeong (KAIST), Kenichi Ikejima (Juntendo Univ., Japan)</i>
09:05-09:25	Obesity and Alcohol Are Deadly Combination to Induce Steatohepatitis	<i>Bin Gao (National Institutes of Health, USA)</i>
09:25-09:45	Alcohol-NAFLD Interactions	<i>Kenichi Ikejima (Juntendo Univ., Japan)</i>
09:45-10:05	Autophagy Regulation in Alcoholic and Non-Alcoholic Liver Steatosis	<i>Sang Geon Kim (Seoul National Univ.)</i>
10:05-10:25	Alcohol-NAFLD Interactions in a Large Korean Cohort Study	<i>Yong Kyun Cho (Sungkyunkwan Univ.)</i>
10:25-10:35	Interaction between CD40L and CD40 Mediates Hepatic Exosomal Delivery to Kupffer Cells in Alcoholic Liver Disease	<i>Kyurae Kim (KAIST)</i>
10:35-10:45	The Effect of Intestinal Flora Modification on Alcoholic Liver Injury in Obese KK-Ay Mice	<i>Kazuyoshi Kon (Juntendo Univ., Japan)</i>
10:45-11:00	Round Table Discussions	
10:20-11:20	Plenary Presentation 1	Real Time Discussion <i>Kwan Sik Lee (Yonsei Univ.), Kwan Soo Byun (Korea Univ.), Ho Seong Han (Seoul National Univ.)</i>
10:20-10:35	ROS-Induced Activation of YAP-1 through a c-Myc Pathway is a Therapeutic Target in Hepatocellular Carcinoma	<i>Yuri Cho (CHA Univ.)</i>
10:35-10:50	Oral L-Carnitine on Quality of Life and Cognition in Covert Hepatic Encephalopathy: A Randomized, Double-Blind, Placebo-Controlled (HELIOS) Study	<i>Eileen L. Yoon (Inje Univ.)</i>
10:50-11:05	Impact of Existing Liver Disease on Clinical Outcomes of COVID-19: A Multicenter Study	<i>Yu Rim Lee (Kyungpook National Univ.)</i>
11:05-11:20	Adverse Effect of Sarcopenic Obesity on Postoperative Complications after Major Hepatectomy in Patients with Hilar Cholangiocarcinoma	<i>Youngju Ryu (Sungkyunkwan Univ.)</i>

11:00-13:00	ISALPDC 2. Novel Cellular and Organ Crosstalk in Alcoholic Liver Disease	<i>Bin Gao (National Institutes of Health, USA), Yasuko Iwakiri (Yale Univ., USA)</i>
11:00-11:20	Neuroendocrine-Fat-Liver Axis	<i>Laura E. Nagy (Cleveland Clinic, USA)</i>
11:20-11:40	Lymphatic System and Organ Crosstalk	<i>Yasuko Iwakiri (Yale Univ., USA)</i>
11:40-12:00	Liver-Lung Crosstalk	<i>Gavin E. Arteel (Univ. of Pittsburgh, USA)</i>
12:00-12:20	Glutamate/mGluR5-mediated Endocannabinoid in Alcoholic Fatty Liver	<i>Won-IL Jeong (KAIST)</i>
12:20-12:30	CYP2E1 Regulation of Ethanol-Induced Intestinal miRNAs in Liver Injury	<i>Je-Hyun Yoon (Medical Univ. of South Carolina, USA)</i>
12:30-12:40	Chronic Alcohol Consumption Alters the Phenotype of F4/80+CD11b+ Bone Marrow Cells by Neuro-Metabolic Signaling Pathway	<i>Young-Ri Shim (KAIST)</i>
12:40-13:00	Round Table Discussions	
11:30-12:00	State-of-the-Art Lecture	<i>Seung Woon Paik (Sungkyunkwan Univ.)</i>
	Past, Present, and Future of Precision Hepatology: Where Do We Need to Go?	<i>W. Ray Kim (Stanford Univ., USA)</i>
11:30-12:40	PG2. Current Issues in Chronic Hepatitis C ^(*K)	
11:30-11:40	Case Presentation and Key Questions	<i>Hyun Woong Lee (Yonsei Univ.)</i>
11:40-12:00	Retreatment Options for Chronic Hepatitis C after Oral Direct-Acting Antiviral Agent Failure	<i>Jung Hyun Kwon (The Catholic Univ. of Korea)</i>
12:00-12:20	Risks and Benefits of Oral Direct-Acting Antiviral Agent Therapy in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma	<i>Nae-Yun Heo (Inje Univ.)</i>
12:20-12:40	Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C Patients Who Achieved Sustained Virological Response	<i>Yun Bin Lee (Seoul National Univ.)</i>
12:10-12:55	Satellite Symposium 1 [Bayer]	
12:40-13:25	Satellite Symposium 2 [Gilead]	
13:00-13:45	Satellite Symposium 3 [AbbVie]	
13:00-14:30	KLCA Symposium 1. The Changing Landscape and New Evidences in Treatment Strategies for Hepatocellular Carcinoma	Real Time Discussion <i>Joong-Won Park (National Cancer Center Korea), Jung-Hwan Yoon (Seoul National Univ.)</i>
13:00-13:20	Current Evidences and Future Perspectives for the Treatment of Advanced Hepatocellular Carcinoma	<i>Jeong Won Jang (The Catholic Univ. of Korea)</i>
13:20-13:40	When Should We Consider Systemic Therapy in BCLC Stage B Hepatocellular Carcinoma?	<i>Hyung Joon Yim (Korea Univ.)</i>
13:40-14:00	Therapeutic Efficacy of Transarterial-Based Treatment vs. Targeted Therapy in Advanced Hepatocellular Carcinoma	<i>Sadahisa Ogasawara (Chiba Univ., Japan)</i>
14:00-14:20	Optimizing Therapeutic Efficacy with Systemic Treatment and Radiotherapy in Hepatocellular Carcinoma	<i>Jinsil Seong (Yonsei Univ.)</i>
14:20-14:30	Discussion	
13:30-14:40	PG3. Consensus on the Management of Nonalcoholic Fatty Liver Disease ^(*K)	
13:30-13:40	Case Presentation and Key Questions	<i>Young-Joo Jin (Inha Univ.)</i>
13:40-14:00	Assessment of Co-Morbidities in Patients with Nonalcoholic Fatty Liver Disease	<i>Jung Il Lee (Yonsei Univ.)</i>
14:00-14:20	Pathogenesis and Management of Non-Obese Nonalcoholic Fatty Liver Disease	<i>Hwi Young Kim (Ewha Womans Univ.)</i>
14:20-14:40	Currently Available Treatment Strategy in Patients with Nonalcoholic Steatohepatitis and Metabolic Syndrome	<i>Won Sohn (Sungkyunkwan Univ.)</i>

14:00-15:10	General Oral Presentation 1	Real Time Discussion <i>Myung Seok Lee (Hallym Univ.), Byung Ik Kim (Sungkyunkwan Univ.)</i>
14:00-14:10	Kahweol Activates the NRF2/HO-1 Pathway by Decreasing Keap1 Expression Independently of p62 and Autophagy Pathways	<i>Hye-Young Seo (Keimyung Univ.)</i>
14:10-14:20	TIP-47-Accelerates Fatty Change of Liver During Alcohol Ingestion in HBx Transgenic Mice	<i>Hoon Gil Jo (Wonkwang Univ.)</i>
14:20-14:30	Hepatitis B Core-Related Antigen Is a Satisfactory Marker in Differentiating Hepatitis B e Antigen-Positive Chronic Infection and Hepatitis B e Antigen-Positive Chronic Hepatitis	<i>Han Ah Lee (Korea Univ.)</i>
14:30-14:40	All Cause of Mortality and Incidence of Hepatocellular Carcinoma Among Chronic Hepatitis C Patients in South Korea: A Prospective, Multicenter Cohort Study	<i>Gwang Hyeon Choi (Seoul National Univ.)</i>
14:40-14:50	Weight Gain during Early Adulthood, Trajectory of Body Shape and the Risk of Nonalcoholic Fatty Liver Disease Among Women: A Prospective Cohort Study	<i>Mi Na Kim (CHA Univ.)</i>
14:50-15:00	Bedside Risk-Scoring Model for Prediction of 30 Days' Mortality in Patients with Cirrhosis Underwent Endoscopic Band Ligation for Acute Variceal Bleeding	<i>Jung Hee Kim (Hallym Univ.)</i>
15:00-15:10	Population-Based Epidemiology of Primary Biliary Cholangitis in South Korea	<i>Kyung-Ah Kim (Inje Univ.)</i>
14:40-15:50	LCGSJ-KLCA Joint Symposium. Similarities and Differences in HCC Management	Real Time Discussion <i>Shoji Kubo (Osaka City Univ., Japan), Jin Wook Chung (Seoul National Univ.)</i>
14:40-14:55	Current Approaches to the Treatment of Early HCC in Japan	<i>Shuichiro Shiina (Juntendo Univ., Japan)</i>
14:55-15:10	Current Approaches to the Treatment of Early HCC in Korea	<i>Myeong Jun Song (The Catholic Univ. of Korea)</i>
15:10-15:25	Selection of Particle Beam vs. Photon Beam Radiation Therapy for HCC: Japanese Experience	<i>Hideyuki Sakurai (Univ. of Tsukuba, Japan)</i>
15:25-15:40	Selection of Particle Beam vs. Photon Beam Radiation Therapy for HCC: Korean Experience	<i>Hee Chul Park (Sungkyunkwan Univ.)</i>
15:40-15:50	Discussion	
14:50-16:00	PG4. Assessment and Management of Liver Cirrhosis Complications (*K)	
14:50-15:00	Case Presentation and Key Questions	<i>Young-Joo Jin (Inha Univ.)</i>
15:00-15:20	How to Assess Minimal Hepatic Encephalopathy in Patients with Liver Cirrhosis?	<i>Eileen L. Yoon (Inje Univ.)</i>
15:20-15:40	When and How to Use Anticoagulants for Benign Portal Vein Thrombosis in Patients with Liver Cirrhosis	<i>Young Kul Jung (Korea Univ.)</i>
15:40-16:00	Update of Beta Blocker and Albumin Use for Patients with Decompensated Liver Cirrhosis	<i>Ki Tae Yoon (Pusan National Univ.)</i>
15:10-18:10	Abdominal Ultrasonography Training Course for Certified Trainer (*K)	
15:10-15:30	Introduction to Ultrasonography Training Program for Trainer and Trainee of KASL	<i>Moon-Young Kim (Yonsei Univ. Wonju)</i>
15:30-15:50	Useful Tips for Setting-up of Ultrasound Rooms	<i>Soo Young Park (Kyungpook National Univ.)</i>
15:50-16:10	Experience of Ultrasonography Education Programs for Residents and Fellows in Korea	<i>Jun Yong Park (Yonsei Univ.)</i>
16:10-16:30	Tips for Ultrasonography Examination in Patients with Poor Sonographic Window	<i>Jaeyoun Cheong (Ajou Univ.)</i>
16:30-16:50	Contrast-enhanced Ultrasonography in the Diagnosis of Focal Liver Lesions	<i>Sae Hwan Lee (Soonchunhyang Univ.)</i>
16:50-17:10	Ultrasonography-guided Procedures: Percutaneous Drainage Insertion and Liver Biopsy	<i>Seung Whan Cha (Yonsei Univ. Wonju)</i>
17:10-17:30	Clinical Application of Liver Stiffness and Viscosity Measurement Using Shear Wave Elastography	<i>Sang Gyune Kim (Soonchunhyang Univ.)</i>
17:30-17:50	Technological advancement in Ultrasonography: Real-Time Fusion Imaging of Liver Ultrasonography with CT or MRI	<i>Ji Young Kwon (Canon Medical Systems)</i>
17:50-18:10	Comparison Between Transabdominal Ultrasonography and Endoscopic Ultrasonography for the Diagnosis of Pancreatobiliary Disease	<i>Young Koog Cheon (Konkuk Univ.)</i>

16:00-17:30	KASL Symposium 2. New Insights to Unanswered Issues in Treatment for Chronic Hepatitis B	Real Time Discussion <i>Seung Kew Yoon (The Catholic Univ. of Korea), Kyun-Hwan Kim (Sungkyunkwan Univ.)</i>
16:00-16:20	Exploring Unrecognized Risks in Immune Tolerant Phase of Chronic Hepatitis B	<i>Young-Suk Lim (Univ. of Ulsan)</i>
16:20-16:40	Clonal Hepatocyte Expansion and Hepatitis B Virus Integration	<i>Patrick Kennedy (Queen Mary Univ. of London, UK)</i>
16:40-17:00	Effect of Current and Novel Antivirals on the Prevention of Hepatocellular Carcinoma: Beyond Viral Suppression	<i>George V. Papatheodoridis (National and Kapodistrian Univ. of Athens, Greece)</i>
17:00-17:20	Functional Cure of Chronic Hepatitis B and Beyond	<i>Man-Fung Yuen (The Univ. of Hong Kong, China)</i>
17:20-17:30	Discussion	
16:10-17:30	PG for Basic Research (**K)	
16:10-16:30	Assessment of Mitochondrial Function in Liver Research	<i>Hyon-Seung Yi (Chungnam National Univ.)</i>
16:30-16:50	Selection and Utilization of Murine Models in Liver Research	<i>Seung-Jin Kim (Kangwon National Univ.)</i>
16:50-17:10	Basic Understanding of Genomics and Proteomics Study	<i>Ju-Seog Lee (UT MD Anderson Cancer Center, USA)</i>
17:10-17:30	A Noble and Powerful Tool: Single Cell RNA Sequencing	<i>Young Seok Ju (KAIST)</i>

DAY 2 Friday, August 14, 2020

08:30-10:50	Policy Symposium. Nationwide Policies to Eliminate Hepatitis C	Real Time Discussion <i>Dong Jin Suh (Korean Liver Foundation), W. Ray Kim (Stanford Univ., USA), Han Chu Lee (Univ. of Ulsan)</i>
08:30-09:00	Hepatitis C Elimination Program in Taiwan: "The Taiwan Hepatitis C Policy Guideline 2018 - 2025"	<i>Chien-Jen Chen (Former Vice President of Taiwan, Academia Sinica, Taiwan)</i>
09:00-09:20	HCV Elimination in Taiwan: What and How We Have Achieved from the Beginning till Today	<i>Jia-Horng Kao (National Taiwan Univ., Taiwan)</i>
09:20-09:40	HCV Elimination in Japan: The Japanese Policy and Outcome	<i>Tatsuya Kanto (National Center for Global Health and Medicine, Japan)</i>
09:40-10:00	National Policies on Hepatitis C in Korea	<i>Hyung-Min Lee (Korea Centers for Disease Control & Prevention)</i>
10:00-10:20	Current Status and Suggestions for Hepatitis C Control in Korea	<i>Do Young Kim (Yonsei Univ.)</i>
10:20-10:50	Panel Discussion	
08:30-10:20	ISALPDC 3. Alcohol Promotion of Cancer	Real Time Discussion <i>Wen Xing Ding (Univ. of Kansas, USA), Yingzi Yang (Harvard Univ., USA)</i>
08:30-08:50	Hippo Pathway Regulation of Liver Inflammation and Cancer	<i>Yingzi Yang (Harvard Univ., USA)</i>
08:50-09:10	Complement C3, tRNA-derived Fragments Gly-tRFs, and Alcoholic Liver Disease	<i>Songqing He (Guangxi Medical Univ., China)</i>
09:10-09:30	Autophagy and Cancer	<i>Wen-Xing Ding (Univ. of Kansas, USA)</i>
09:30-09:50	Risk Factors for Alcohol-Related Hepatocellular Carcinoma	<i>Makiko Taniai (Tokyo Women's Medical Univ., Japan)</i>
09:50-10:00	Catecholamine Signaling Pathway Protects Alcoholic Fatty Liver by Inducing Growth Differentiation Factor 15	<i>Hee-Hoon Kim (KAIST)</i>
10:00-10:20	Round Table Discussions	

08:50-09:50	Basic Science Workshop	
08:30-08:50	Transcriptomic Signature of Nonalcoholic Fatty Liver Disease	<i>Murim Choi (Seoul National Univ.)</i>
08:50-09:10	Immunologic Circuits of Hepatocellular Carcinoma	<i>Su Jong Yu (Seoul National Univ.)</i>
09:10-09:30	Interactive Interface between Gut Microbiome and Immune in Alcohol-Related Liver Disease	<i>Bernd Schnabl (Univ. of California San Diego, USA)</i>
09:30-09:50	Novel Immunomodulating Pharmabiotics for Hepatocellular Carcinoma	<i>Han Soo Park (GIST)</i>
09:50-10:50	Special Interest Group Forum. Clinical Issues in Autoimmune Liver Disease	
09:50-10:10	Pathology of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Overlap Syndrome	<i>Masayoshi Kage (Kurume Univ., Japan)</i>
10:10-10:30	Autoimmune Hepatitis: From Bench to Clinic	<i>Xiong Ma (Shanghai Jiao Tong Univ., China)</i>
10:30-10:50	Primary Biliary Cholangitis: Unsolved Issues and New Treatment	<i>Gideon M. Hirschfield (Toronto Centre for Liver Disease, Canada)</i>
10:30-12:45	ISALPDC 4. Translational Studies and Public Health on Alcoholic Liver Disease	Real Time Discussion <i>Shiv Kumar Sarin (Institute of Liver and Biliary Science, India), Suthat Liangpunsakul (Indiana Univ., USA)</i>
10:30-10:50	Prognostic Potential of LncRNAs for Alcoholic Liver Disease Patients	<i>Suthat Liangpunsakul (Indiana Univ., USA)</i>
10:50-11:10	Predictors of Steroid Non-Response and New Approaches in Severe Alcoholic Hepatitis	<i>Shiv Kumar Sarin (Institute of Liver and Biliary Science, India)</i>
11:10-11:30	Global and Regional Impacts of Alcohol Use on Public Health	<i>Dong Joon Kim (Hallym Univ.)</i>
11:30-11:50	Impact of Genetic Traits and Drinking Mode on Alcoholic Liver Disease in China	<i>Jia Xiao (Fujian Normal Univ., China)</i>
11:50-12:10	TAPPY: Multi-Professional Care of Alcoholic Patients	<i>Masahiro Kikuchi (Tokyo Medical Center, Japan)</i>
12:10-12:20	The Evolution of Liver Donor Liver Transplantation for Alcoholic Liver Cirrhosis in a High-Volume Center: The Eastern Perspective	<i>Jeffrey Samuel Co (Kaohsiung Chang Memorial Hospital, Taiwan)</i>
12:20-12:40	Round Table Discussions	
12:40-12:45	Closing Remarks	
11:00-12:00	Plenary Presentation 2	Real Time Discussion <i>Jin Mo Yang (The Catholic Univ. of Korea), Chul Ju Han (Korea Cancer Center Hospital), Yang Won Nah (Univ. of Ulsan)</i>
11:00-11:15	Serum miRNA as a Useful Diagnostic Biomarker for Diagnosis of NASH and a Clue for Disease Progression Pathway in NAFLD Patients	<i>Young-Sun Lee (Korea Univ.)</i>
11:15-11:30	Association of Metabolic Risk Factors with Risks of Cancer and All-Cause Mortality in Patients with Chronic Hepatitis B Virus Infection: A Korean Nationwide Cohort Study	<i>Yun Bin Lee (Seoul National Univ.)</i>
11:30-11:45	Regorafenib versus Nivolumab after Sorafenib Failure: Real-World Data in Patients with Hepatocellular Carcinoma	<i>Won-Mook Choi (Univ. of Ulsan)</i>
11:45-12:00	Circulating Cancer Stem Cells in Hepatocellular Carcinoma: A Pilot Study of Prediction for Tumor Recurrence after Living Donor Liver Transplantation	<i>Hyeo Seong Hwang (Yonsei Univ.)</i>
12:10-12:55	Satellite Symposium 4 [Yuhan]	
12:10-12:55	Satellite Symposium 5 [Eisai]	
12:10-12:55	Satellite Symposium 6 [BMS]	

13:00-14:10	KLTS-KAHBPS-KLCA Joint Symposium. Treatment Options for HCC beyond the Milan Criteria in Patients with Marginal Liver Function	Real Time Discussion Jong Young Choi (The Catholic Univ. of Korea), Shin Hwang (Univ. of Ulsan)
13:00-13:20	Locoregional Therapy	Yoon Jun Kim (Seoul National Univ.)
13:20-13:40	Down-Staging Living Donor Liver Transplantation	Jae Geun Lee (Yonsei Univ.)
13:40-14:00	Is There a Role for TKIs and Immune Checkpoint Inhibitors?	Thomas Yau (The Univ. of Hong Kong, China)
14:00-14:10	Discussion	
13:00-14:00	KLCA Symposium 2. Updates in Diagnosis and Biomarkers of Hepatocellular Carcinoma	
13:00-13:20	Established and Potential Biomarkers of Hepatocellular Carcinoma with Focus on Recent Clinical Trials	Joong-Won Park (National Cancer Center Korea)
13:20-13:40	Imaging Biomarkers in the Era of Precision Medicine	Sun Young Lee (Yonsei Univ.)
13:40-14:00	Pathologic Biomarkers that Indicate the Aggressiveness and Prognosis of Hepatocellular Carcinoma	Young Nyun Park (Yonsei Univ.)
13:30-14:40	General Oral Presentation 2	Real Time Discussion Young Oh Kweon (Kyungpook National Univ.), Sang-Jae Park (National Cancer Center)
13:30-13:40	Serum Small Extracellular Vesicle-Derived LINC00853 as a Novel Diagnostic Marker for Early Hepatocellular Carcinoma	Suna Sung (Ajou Univ.)
13:40-13:50	Current Status of Ultrasonography Examination Operated by National Cancer Surveillance Program for Hepatocellular Carcinoma: Multi-Center Large-Scale Research	Jeong-Ju Yoo (Soonchunhyang Univ.)
13:50-14:00	Development of Machine Learning-Based Clinical Decision Support System for Hepatocellular Carcinoma	Gwang Hyeon Choi (Seoul National Univ.)
14:00-14:10	Proton Beam Radiotherapy versus Radiofrequency Ablation Treatment in Patients with Recurrent Hepatocellular Carcinoma: A Randomized Controlled Phase 3 Non-Inferiority APROH Trial	Joong-Won Park (National Cancer Center Korea)
14:10-14:20	Clinical Significance of Intraoperative Bile Culture in Surgery Including Bile Duct Resection	Youngju Ryu (Sungkyunkwan Univ.)
14:20-14:30	Medium not too High Intensity versus Medium not too Low Intensity Exercise Effect on Fatty Liver – Post Cholecystectomy with Metabolic Syndrome: A Comparison Study	Alvin Wiharja (Svarga e-Motion Sanctuary, Indonesia)
14:30-14:40	Development of Novel Multivariable Logistic Regression Model for Predicting Graft Failure within 2 Weeks and 4 Weeks after Liver Transplantation	Jinsoo Rhu (Sungkyunkwan Univ.)
14:10-15:10	KAHBPS-KLTS Joint Symposium. Optimal Use of ICG Fluorescence Technology in Daily Practice	
14:10-14:30	Tumor Localization in Oncologic Surgery	Masaki Ueno (Wakayama Medical Univ., Japan)
14:30-14:50	Anatomical Liver Resection	Dai Hoon Han (Yonsei Univ.)
14:50-15:10	Donor Hepatectomy	Young Rock Choi (Seoul National Univ.)
14:20-15:20	KASL Plenary Presentation	Real Time Discussion Seong Gyu Hwang (CHA Univ.), Kwon Yoo (Ewha Womans Univ.)
14:20-14:35	Therapeutic Effects of Function-Enhanced PRL-1 in Placenta-Derived Mesenchymal Stem Cells on Accelerating Hepatic Functions via Mitochondrial Dynamics in Liver Diseases	Jae Yeon Kim (CHA Univ.)
14:35-14:50	The Role of Urinary Biomarkers in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study	Jeong-Ju Yoo (Soonchunhyang Univ.)
14:50-15:05	Lean Non Alcoholic Fatty Liver Disease Increases Cardiovascular Risk more than Obese Non Alcoholic Fatty Liver Disease	Yuna Kim (Yonsei Univ.)
15:05-15:20	Multicenter Analysis of Clinical Features and Treatment Outcomes of COVID-19 Patients with Hepatic Impairment	Jeong Eun Song (Daegu Catholic Univ.)

14:40-15:25	Satellite Symposium 7 [ILDONG]	
15:20-16:40	KASL Symposium 3. Exploration of Biomarkers in Liver Diseases	
15:20-15:40	New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Infection	<i>Il Han Song (Dankook Univ.)</i>
15:40-16:00	Non-Invasive Diagnosis and Biomarkers in Alcohol-Related Liver Disease	<i>Suthat Liangpunsakul (Indiana Univ., USA)</i>
16:00-16:20	Quantitative Imaging Biomarker in the Assessment of Hepatic Fibrosis and Steatosis	<i>Woo Kyoung Jeong (Sungkyunkwan Univ.)</i>
16:20-16:40	Clinical Application of Liquid Biopsy as a Prognostic Biomarker in Hepatocellular Carcinoma	<i>Soo Young Park (Kyungpook National Univ.)</i>
15:30-17:00	KASL-KAHBPS-KLTS Joint Symposium. How to Improve Outcome in Critically Ill Patients Awaiting Liver Transplantation	Real Time Discussion <i>Soon Ho Um (Korea Univ.), Hee Chul Yu (Chonbuk National Univ.)</i>
15:30-15:50	Liver Transplantation for Patients with Severe Alcoholic Hepatitis: Inside Stories of Patient Selection and Pretransplant Management	<i>Philippe Mathurin (Chu De Lille, France)</i>
15:50-16:10	Risk Stratification and Optimal Management for Liver Transplantation in Acute-on-Chronic Liver Failure	<i>Dong Hyun Sinn (Sungkyunkwan Univ.)</i>
16:10-16:30	Risk Stratification and Optimal Management for Liver Transplantation in Acute Liver Failure	<i>Young-dong Yu (Korea Univ.)</i>
16:30-16:50	How to Improve Post-Transplant Outcomes in Patients with High MELD Scores	<i>Dong-Hwan Jung (Univ. of Ulsan)</i>
16:50-17:00	Discussion	
17:00-17:30	Closing and Award Ceremony	